Affiliation: University College London
- A mouse monoclonal antibody against Epstein-Barr virus envelope glycoprotein 350 prevents infection both in vitro and in vivoTanzina Haque
Molecular and Clinical Virology, University of Edinburgh, Summerhall, Edinburgh, United Kingdom
J Infect Dis 194:584-7. 2006..No adverse reactions were seen in the adult or in 3 of the transplant recipients. The remaining patient developed a hypersensitivity reaction, thus underlining the need to humanize the MAb...
- Soluble CD30: a serum marker for Epstein-Barr virus-associated lymphoproliferative diseasesTanzina Haque
Department of Virology, Royal Free Hospital, UCL Medical School, London, United Kingdom
J Med Virol 83:311-6. 2011..In both cases there was a significant correlation between sCD30 and EBV DNA levels in plasma (P < 0.0001). This study demonstrates that sCD30 and EBV DNA levels can be used as potential markers for diagnosis of IM and PTLD...
- Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trialTanzina Haque
Clinical and Molecular Virology Laboratory, University of Edinburgh, Edinburgh, United Kingdom
Blood 110:1123-31. 2007..Our results show that allogeneic CTLs are a safe and rapid therapy for PTLD, bypassing the need to grow CTLs for individual patients. The response rate in this poor prognosis patient group is encouraging...
- Establishment and characterization of a bank of cytotoxic T lymphocytes for immunotherapy of epstein-barr virus-associated diseasesGwen M Wilkie
Laboratory for Clinical and Molecular Virology, The University of Edinburgh, Summerhall, Edinburgh, United Kingdom
J Immunother 27:309-16. 2004..Additionally, other patient groups, such as those with EBV-positive Hodgkin disease, may benefit from CTL treatment...
- Incidence and dynamics of Epstein-Barr virus reactivation after alemtuzumab-based conditioning for allogeneic hematopoietic stem-cell transplantationBen Carpenter
Department of Haematology, Royal Free Hampstead NHS Trust, London, United Kingdom
Transplantation 90:564-70. 2010..The pattern of EBV reactivation in patients receiving allogeneic HSCT, incorporating in vivo or in vitro alemtuzumab as the method of TCD, is not known...
- Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trialPaul D Griffiths
Centre for Virology, UCL Medical School, London, UK
Lancet 377:1256-63. 2011..Values of viral load correlate with development of end-organ disease and are moderated by pre-existing natural immunity. Our aim was to determine whether vaccine-induced immunity could do likewise...
- Epitope specificity and clonality of EBV-specific CTLs used to treat posttransplant lymphoproliferative diseaseKaren A McAulay
Clinical and Basic Virology Laboratory, School of Biomedical Sciences, University of Edinburgh, Summerhall, Edinburgh, UK
J Immunol 182:3892-901. 2009..These observations should be considered when designing and implementing CTL therapies...
- Cytolytic mechanisms and T-cell receptor Vbeta usage by ex vivo generated Epstein-Barr virus-specific cytotoxic T lymphocytesVictoria J Vanhoutte
Clinical and Molecular Virology, University of Edinburgh, Summerhall, Edinburgh, UK
Immunology 127:577-86. 2009..001). This difference was not observed with Fas ligand or perforin expression. Our results provide insight into the basic characteristics of ex-vivo-generated CTL...
- Immunotherapy and vaccination after transplant: the present, the futureVincent C Emery
Department of Infection, University College London, Rowland Hill Street, Hampstead, London NW3 2QG, UK
Infect Dis Clin North Am 24:515-29. 2010..At present, many of these approaches in transplant recipients have focused on infections such as human cytomegalovirus, but the opportunity to use these examples as proof of concept for other infections is discussed...
- The prevalence of occult hepatitis B virus (hbv) infection in a large multi-ethnic haemodialysis cohortLuciana Sowole
Department of Virology, Royal Free Hospital, Pond Street, Hampstead, London, NW3 2QG, UK
BMC Nephrol 16:12. 2015..Haemodialysis patients are at increased risk of exposure to blood borne viruses. To reduce transmission in the UK, all haemodialysis patients are regularly screened, and if susceptible to Hepatitis B virus (HBV) infection, vaccinated...
- Characteristics of Epstein-Barr viraemia in adult liver transplant patients: a retrospective cohort studyNeil Halliday
Department of Virology, Royal Free London NHS Foundation Trust, London, UK
Transpl Int 27:838-46. 2014..001) but shortened with ganciclovir exposure (P = 0.06). Younger patients were more likely to have high peak viral loads (P = 0.07). No clinical signs or symptoms or adverse outcomes were associated with EBV reactivation. ..
- Prospective monitoring of Epstein-Barr virus DNA in adult renal transplant recipients during the early posttransplant period: role of mycophenolate mofetilMichael V Holmes
Centre for Virology, Royal Free Campus, UCL Medical School, London, United Kingdom
Transplantation 87:852-6. 2009..Epstein-Barr virus (EBV) is associated with posttransplant lymphoproliferative disease. We monitored the incidence of EBV viraemia in adult renal transplant recipients and investigated the association with clinical parameters...
- Establishment and operation of a Good Manufacturing Practice-compliant allogeneic Epstein-Barr virus (EBV)-specific cytotoxic cell bank for the treatment of EBV-associated lymphoproliferative diseaseMark A Vickers
Scottish National Blood Transfusion Service, Aberdeen, London, UK University of Aberdeen, Aberdeen, London, UK
Br J Haematol 167:402-10. 2014..Thus, this third party donor-derived EBV-specific CTL cell bank can supply most patients with appropriately matched cells and most recipients have good outcomes. ..
- Evaluation of sequencing of HCV core/E1, NS5A and NS5B as a genotype predictive tool in comparison with commercial assays targeting 5'UTRAdele L McCormick
Department of Virology, Royal Free London NHS Foundation Trust, London, UK Electronic address
J Clin Virol 66:56-9. 2015..Hepatitis C virus (HCV) genotyping is required for tailoring the dose and duration of antiviral therapy, predicting virological response rates, and selecting future treatment options...
- Performance of the architect EBV antibody panel for determination of Epstein-Barr virus infection stage in immunocompetent adolescents and young adults with clinical suspicion of infectious mononucleosisAlvaro Guerrero-Ramos
Department of Virology, Royal Free London NHS Foundation Trust, London, United Kingdom
Clin Vaccine Immunol 21:817-23. 2014..Concomitant testing for CMV is strongly recommended to aid in the interpretation of EBV serological patterns. ..
- Interleukin 28B gene polymorphisms and Epstein-Barr virus-associated lymphoproliferative diseasesEla Akay
Department of Virology, Royal Free Hospital, London, UK
Intervirology 57:112-5. 2014....
- Treatment of Epstein-Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cellsTanzina Haque
Laboratory for Clinical and Molecular Virology, University of Edinburgh, Edinburgh EH9 1QH, UK
Lancet 360:436-42. 2002..Since tumour growth results from inadequate T-cell control of latent EBV, new immunotherapeutic approaches to treatment are being pioneered...
- Epstein-Barr virus load correlating with clinical manifestation and treatment response in a patient with angioimmunoblastic T-cell lymphomaManuel Battegay
Division of Infectious Diseases, Department of Internal Medicine and Research, University Hospital of Basel, Basel, Switzerland
Antivir Ther 9:453-9. 2004..This case report demonstrates the close association of EBVL and AITL and a beneficial effect of antiviral therapy at an initial stage of disease manifestation...
- Treatment of Epstein-Barr-virus-associated primary CNS B cell lymphoma with allogeneic T-cell immunotherapy and stem-cell transplantationRobert F Wynn
Royal Manchester Children s Hospital, University of Manchester, UK
Lancet Oncol 6:344-6. 2005
- Non-myeloablative bone marrow transplantation in an adult with Wiskott-Aldrich syndromeHilary J Longhurst
Department of Immunopathology, St Bartholomew s Hospital, London, UK
Br J Haematol 116:497-9. 2002..We describe a non-myeloablative transplant of a 26-year-old man with WAS, undertaken because of severe infections and vasculitis. Partial engraftment and immunorestoration were achieved. The patient is well 1 year post transplantation...